Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk

Abstract

Reduction of HCC development was more significant in CHB patients at higher HCC risk with IFN-based therapy than NAs treatment.